Silence Therapeutics
SLN
6 hedge funds and large institutions have $56.4M invested in Silence Therapeutics in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
1% more capital invested
Capital invested by funds: $55.9M → $56.4M (+$471K)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.32% less ownership
Funds ownership: 2.85% → 2.53% (-0.32%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$7.44M |
| 2 |
Morgan Stanley
New York
|
-$14.4K |
| 3 |
SG Americas Securities
New York
|
-$1.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LOAMU
1
Lombard Odier Asset Management (USA)
New York
| $21.6M | -$7.44M | -285,007 | -24% |
|
|
BI
2
BVF Inc
San Francisco,
California
| $17M | – | – | – |
|
3
Adage Capital Partners
Boston,
Massachusetts
| $11.6M | – | – | – |
|
|
CCM
4
Consonance Capital Management
New York
| $5.78M | – | – | – |
|
|
5
Morgan Stanley
New York
| $250K | -$14.4K | -553 | -5% |
|
|
6
SG Americas Securities
New York
| $138K | -$1.12K | -43 | -0.8% |
|
SLN Hedge Fund Activity: Q2 2021 in Review
6 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2021, worth a combined $56.4M — up 0.84% from $55.9M a quarter earlier.
Fund positioning in SLN was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $7.44M.
- 6 institutional investors held Silence Therapeutics (SLN) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $56.4M of Silence Therapeutics stock for Q2 2021, up 0.84% quarter-over-quarter.
- 0 funds opened new Silence Therapeutics positions in Q2 2021 and 0 closed out.
- The largest Silence Therapeutics seller in Q2 2021 was Lombard Odier Asset Management (USA), an estimated $7.44M sold.
Based on aggregated 13F filings for Q2 2021.